- SS Innovations, developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, up 39.4% year over year.
- First-half revenue reached $25.0 million, a 65.6% increase from the same period in 2025.
- The company’s SSi Mantra installations rose 30.4% to 30 systems during the quarter.
- The installed base reached 224 SSi Mantra systems across 12 countries, with 12,272 cumulative surgeries performed.
- U.S. and European regulatory milestones could become important catalysts, with the company targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026.
- The company’s telesurgery achievements are extending the clinical profile of SSi Mantra, while system installations remain the primary commercial growth driver.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, delivered another quarter of rapid top-line growth as demand for its SSi Mantra surgical robotic system continued to expand. The company reported second-quarter 2026 revenue of $13.9 million, an increase of 39.4% from $10.0 million a year earlier. Gross profit increased 20.0% to $7.1 million, although gross margin declined to 50.9% from 59.1% in the year-earlier quarter (https://nnw.fm/zxrT1).
At a glance
- Company
- SS Innovations International
- Ticker
- NASDAQ: SSII
- Announcement
- Earnings
Key figures
- Second-quarter 2026 revenue
- $13.9 million
- Second-quarter revenue growth
- 39.4%
- First-half revenue
- $25.0 million
- First-half revenue growth
- 65.6%
- Installed SSi Mantra systems
- 224
- Cumulative surgeries
- 12,272
Products and programs
The stronger comparison comes over the first six months of the year. Revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025. Gross profit increased 77.5% to $12.4 million, while first-half gross margin improved to…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
SS Innovations International reported second-quarter 2026 revenue of $13.9 million, a 39.4% rise from the comparable quarter in 2025. Revenue for the first six months totaled $25.0 million, up 65.6% year over year. The company also reported second-quarter gross profit of $7.1 million, while gross margin was 50.9%, below the year-earlier 59.1%. SSi Mantra system installations increased 30.4% to 30 during the quarter, and the installed fleet stood at 224 across 12 countries. The systems had been used in 12,272 surgeries cumulatively. SS Innovations identified FDA clearance in the first quarter of 2027 and EU CE marking by the end of 2026 as targets. It said telesurgery is contributing to the platform’s clinical profile, while installations are the main commercial growth driver.
Key takeaways
- Second-quarter revenue was $13.9 million, a 39.4% increase compared with the same quarter in 2025.
- First-half revenue reached $25.0 million, up 65.6% year over year.
- The company reported 224 installed SSi Mantra systems across 12 countries and 12,272 cumulative surgeries.
- SS Innovations is targeting FDA clearance by the first quarter of 2027 and EU CE marking by year-end 2026.
SEC filings
Earlier from SS Innovations International
- SS Innovations International (NASDAQ: SSII) Reports Record Q2 Revenue of $13.9M, Up 39.4%
- SS Innovations International (NASDAQ: SSII) Expands Global Footprint on Fast-Growing Robotic Surgery Market
- SS Innovations International (NASDAQ: SSII) Strengthens Leadership as Global Robotic Surgery Expansion Gains Pace
- SS Innovations International (NASDAQ: SSII) Appoints Sarah Romano as Chief Financial Officer
- SS Innovations International (NASDAQ: SSII) Is ‘One to Watch’
